ATE524740T1 - Seprase als krebsmarker - Google Patents
Seprase als krebsmarkerInfo
- Publication number
- ATE524740T1 ATE524740T1 AT08859952T AT08859952T ATE524740T1 AT E524740 T1 ATE524740 T1 AT E524740T1 AT 08859952 T AT08859952 T AT 08859952T AT 08859952 T AT08859952 T AT 08859952T AT E524740 T1 ATE524740 T1 AT E524740T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- seprase
- types
- assessment
- specific
- Prior art date
Links
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 title abstract 6
- 108010072257 fibroblast activation protein alpha Proteins 0.000 title abstract 6
- 239000000439 tumor marker Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 201000011510 cancer Diseases 0.000 abstract 6
- 206010009944 Colon cancer Diseases 0.000 abstract 3
- 208000020816 lung neoplasm Diseases 0.000 abstract 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000026900 bile duct neoplasm Diseases 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96411—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07023897A EP2071337A1 (en) | 2007-12-10 | 2007-12-10 | Seprase as a marker for cancer |
| EP08015310 | 2008-08-29 | ||
| PCT/EP2008/010385 WO2009074275A1 (en) | 2007-12-10 | 2008-12-08 | Seprase as a marker for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE524740T1 true ATE524740T1 (de) | 2011-09-15 |
Family
ID=40373548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08859952T ATE524740T1 (de) | 2007-12-10 | 2008-12-08 | Seprase als krebsmarker |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8980573B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2223115B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5563988B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101202220B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101896818B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE524740T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008335855B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0820793A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2706115A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2223115T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2372442T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010004671A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2223115T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009074275A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8213005B2 (en) | 2003-07-22 | 2012-07-03 | King Saud University | Method for discriminating between benign and malignant prostate tumors |
| EP2297581B1 (en) * | 2008-07-03 | 2013-04-03 | F. Hoffmann-La Roche AG | Asc as a marker for lung cancer |
| NZ702527A (en) | 2009-12-20 | 2016-07-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP2013519095A (ja) * | 2010-02-05 | 2013-05-23 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP6026422B2 (ja) * | 2010-10-20 | 2016-11-16 | ラッシュ ユニバーシティ メディカル センターＲｕｓｈ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 肺がん試験 |
| CN103403555B (zh) | 2011-03-11 | 2015-06-24 | 霍夫曼-拉罗奇有限公司 | Asc作为慢性阻塞性肺病(copd)的标志物 |
| EP2684049A1 (en) * | 2011-03-11 | 2014-01-15 | Roche Diagniostics GmbH | Seprase as marker for chronic obstructive pulmonary disease (copd) |
| CN102435748B (zh) * | 2011-11-25 | 2014-07-16 | 广东药学院 | 一种双抗夹心酶联免疫检测试剂盒及其制备方法 |
| EP3540440B1 (en) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Methods and uses for evaluating renal injury and renal status |
| EA201492284A1 (ru) | 2012-06-27 | 2015-11-30 | Берг Ллк | Применение маркеров в диагностике и лечении рака предстательной железы |
| EP2919910B1 (en) | 2012-11-09 | 2017-12-20 | Roche Diagnostics GmbH | In vitro capture and analysis of circulating tumor cells |
| CN104969071B (zh) * | 2012-11-30 | 2019-09-03 | 迪森德克斯公司 | 用于评估结肠肿瘤的存在或风险的方法 |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US9753037B2 (en) | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| CN103267852B (zh) * | 2013-05-15 | 2015-03-25 | 中国医学科学院北京协和医院 | 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途 |
| KR101619122B1 (ko) | 2013-08-14 | 2016-05-10 | 연세대학교 산학협력단 | 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법 |
| WO2015088947A1 (en) | 2013-12-09 | 2015-06-18 | Rush University Medical Center | Biomarkers of rapid progression in advanced non-small cell lung cancer |
| PL230661B1 (pl) * | 2014-01-29 | 2018-11-30 | Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach | Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc |
| EP2916134B1 (en) * | 2014-03-05 | 2017-08-16 | Roche Diagnostics GmbH | Use of Seprase for differential diagnosis of acute dyspnea |
| CN107428821B (zh) | 2014-12-08 | 2022-06-24 | 博格有限责任公司 | 包括细丝蛋白a的标志物在诊断和治疗前列腺癌中的用途 |
| WO2016146174A1 (en) * | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| CA2982169A1 (en) | 2015-04-10 | 2016-10-13 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| WO2018020530A1 (ja) * | 2016-07-25 | 2018-02-01 | 静岡県 | 肝外胆管癌、肝内胆管癌、又は胆嚢癌の診断用バイオマーカー |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| DE102017010455A1 (de) * | 2017-06-13 | 2018-12-13 | Forschungszentrum Jülich GmbH | Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe |
| CA3074684A1 (en) * | 2017-09-05 | 2019-03-14 | Oncotag Diagnostics Co., Ltd. | Method for diagnosing pancreatic cancer using methionyl-trna synthetase, and pancreatic cancer diagnostic kit using same |
| WO2022007283A1 (zh) * | 2020-07-08 | 2022-01-13 | 深圳霁因生物医药转化研究院 | 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| AU2004286307A1 (en) * | 2003-10-31 | 2005-05-12 | Vitatex, Inc. | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells |
| US7968308B2 (en) * | 2004-10-22 | 2011-06-28 | Danisco Us Inc. | Isolating human antibodies |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN101379069A (zh) * | 2005-12-19 | 2009-03-04 | 塔夫茨大学信托人 | 软蛋白酶抑制剂及其前软形式 |
-
2008
- 2008-12-08 CA CA2706115A patent/CA2706115A1/en not_active Abandoned
- 2008-12-08 EP EP08859952A patent/EP2223115B1/en active Active
- 2008-12-08 PL PL08859952T patent/PL2223115T3/pl unknown
- 2008-12-08 DK DK08859952.7T patent/DK2223115T3/da active
- 2008-12-08 MX MX2010004671A patent/MX2010004671A/es active IP Right Grant
- 2008-12-08 KR KR1020107012678A patent/KR101202220B1/ko not_active Expired - Fee Related
- 2008-12-08 WO PCT/EP2008/010385 patent/WO2009074275A1/en not_active Ceased
- 2008-12-08 CN CN200880119930.1A patent/CN101896818B/zh active Active
- 2008-12-08 ES ES08859952T patent/ES2372442T3/es active Active
- 2008-12-08 BR BRPI0820793-3A patent/BRPI0820793A2/pt not_active IP Right Cessation
- 2008-12-08 JP JP2010537302A patent/JP5563988B2/ja not_active Expired - Fee Related
- 2008-12-08 AU AU2008335855A patent/AU2008335855B2/en not_active Ceased
- 2008-12-08 AT AT08859952T patent/ATE524740T1/de active
-
2010
- 2010-06-02 US US12/791,946 patent/US8980573B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101896818A (zh) | 2010-11-24 |
| AU2008335855B2 (en) | 2012-08-30 |
| AU2008335855A1 (en) | 2009-06-18 |
| CA2706115A1 (en) | 2009-06-18 |
| US8980573B2 (en) | 2015-03-17 |
| US20100240081A1 (en) | 2010-09-23 |
| BRPI0820793A2 (pt) | 2015-06-16 |
| DK2223115T3 (da) | 2011-12-12 |
| JP5563988B2 (ja) | 2014-07-30 |
| KR20100091212A (ko) | 2010-08-18 |
| MX2010004671A (es) | 2010-05-27 |
| WO2009074275A1 (en) | 2009-06-18 |
| EP2223115A1 (en) | 2010-09-01 |
| ES2372442T3 (es) | 2012-01-19 |
| CN101896818B (zh) | 2016-01-20 |
| PL2223115T3 (pl) | 2012-02-29 |
| EP2223115B1 (en) | 2011-09-14 |
| HK1150884A1 (zh) | 2012-01-13 |
| KR101202220B1 (ko) | 2012-11-16 |
| JP2011506941A (ja) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE524740T1 (de) | Seprase als krebsmarker | |
| WO2010072383A8 (en) | Armet as a marker for cancer | |
| ES2505466T3 (es) | Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo | |
| ATE554389T1 (de) | Apex als marker für lungenkrebs | |
| DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| ES2683362T3 (es) | Microvesículas obtenidas a partir de células tumorales | |
| DK2138848T3 (da) | Fremgangsmåde til diagnose og/eller prognose af blærecancer | |
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| DE602007007209D1 (de) | Verwendung des proteins s100a 12 als marker für kolorektalkarzinom | |
| FI2398902T3 (fi) | Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten | |
| EA200801046A1 (ru) | Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro | |
| WO2010051314A3 (en) | Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations | |
| EA201490946A1 (ru) | Способ количественной оценки лечения рака | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
| DE602005014386D1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| JP2006311860A5 (cg-RX-API-DMAC7.html) | ||
| ATE468535T1 (de) | Verwendung von nnmt als marker für lungenkrebs | |
| Kossatz et al. | PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers–first-in-human results | |
| Tirelli et al. | Open questions and novel concepts in oral cancer surgery | |
| ATE412182T1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
| WO2010130839A4 (en) | Cybp as a marker of lung cancer | |
| WO2010085124A3 (ko) | 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2223115 Country of ref document: EP |